Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etigilimab (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Early breast cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Mereo BioPharma; OncoMed Pharmaceuticals

    • Most Recent Events

    • 29 Nov 2021 Results assessing the safety, tolerability, and preliminary efficacy of etigilimab alone (Phase 1a) and in combination with the anti-PD-1 antibody nivolumab (Phase 1b) in patients with locally advanced or metastatic solid tumors, published in the Clinical Cancer Research.
    • 16 Sep 2019 Status changed from active, no longer recruiting to discontinued.
    • 26 Aug 2019 Planned End Date changed from 1 Oct 2019 to 1 Nov 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top